• Price (EUR)2.07
  • Today's Change0.073 / 3.66%
  • Shares traded131.00
  • 1 Year change6.15%
  • Beta--
Data delayed at least 15 minutes, as of Sep 16 2019.
More ▼

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year PDL BioPharma Inc's revenues fell -38.10%from 320.06m to 198.11m. In addition, the company has been unable to reduce the cost of goods sold, selling, general and administrative expenses and interest paid (all as a percentage of sales). This has contributed to a reduction in net income from a gain of 110.75m to a loss of 68.86m.
Gross margin62.50%
Net profit margin33.95%
Operating margin23.80%
Return on assets4.79%
Return on equity6.40%
Return on investment5.02%
More ▼

Cash flow in USDView more

In 2018, cash reserves at PDL BioPharma Inc fell by 132.68m. However, Cash Flow from Investing totalled 56.70m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 13.43m for operations while cash used for financing totalled 175.96m.
Cash flow per share0.3779
Price/Cash flow per share5.09
Book value per share5.76
Tangible book value per share2.59
More ▼

Balance sheet in USDView more

PDL BioPharma Inc appears to have little financial risk as the company holds a substantial amount of cash on its books. In fact, 1.54% of the market capitalization can be attributed to its 394.59m and debt could be paid in full if management chose.
Current ratio10.43
Quick ratio10.00
Total debt/total equity0.1932
Total debt/total capital0.1619
More ▼

Growth rates in USD

SmartText is unavailable
Div yield(5 year avg)5.89%
Div growth rate (5 year)--
Payout ratio (TTM)0.00%
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago
More ▼
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.